Company Inventiva

Equities

IVA

FR0013233012

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

Ratings for Inventiva

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Euronext Paris Other stock markets 09:05:20 29/04/2024 pm IST			5-day change	1st Jan Change
2.97 ^EUR	-1.00%		-6.90%	-27.47%

22/04	Inventiva: UBS Group falls below 5% threshold	CF
18/04	Transcript : Inventiva S.A. - Special Call

Inventiva is a biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. The group is developing two drug candidates - lanifibranor and odiparcil - in non-alcoholic steatohepatitis (« NASH ») and mucopolysaccharidosis (« MPS ») respectively, as well as a portfolio of several programs in the preclinical stage. Lanifibranor, is currently in a pivotal Phase III clinical trial « NATiV3 » for the treatment of patients with MASH/NASH and Odiparcil is currently in Phase IIa for the treatment of type VI MPS. As part of Inventiva's decision to focus clinical efforts on the development of Lanifibranor, it suspended clinical efforts relating to Odiparcil and is reviewing available options with respect to its potential further development.

Meanwhile, Inventiva is in the process of selecting an oncology drug candidate for the Hippo signaling pathway.

Number of employees: 122

EUR in Million	2022	Weight	2023	Weight	Delta
Oral Small Molecule Therapies 100.0 %	12	100.0 %	17	100.0 %	+43.50%

EUR in Million	2022	Weight	2023	Weight	Delta
Japan 72.9 %	-	-	13	72.9 %	-
China 26.4 %	12	99.0 %	5	26.4 %	-61.76%
France 0.7 %	0	1.0 %	0	0.7 %	-5.60%

Managers	Title	Age	Since
Pierre Broqua FOU	Founder	62	27/11/27
Frédéric Cren CEO	Chief Executive Officer	58	27/11/27
Jean Volatier DFI	Director of Finance/CFO	59	01/12/01
Alice Roudot-Ketelers COO	Chief Operating Officer	53	01/21/01
Michael P. Cooreman CTO	Chief Tech/Sci/R&D Officer	66	01/20/01
Eric Marie Albert Duranson LAW	General Counsel	50	01/21/01
Nathalie Harroy HRO	Human Resources Officer	57	01/12/01
David Nikodem PRN	Corporate Officer/Principal	54	01/18/01

Members of the board	Title	Age	Since
Chris Buyse BRD	Director/Board Member	59	14/17/14
Annick Schwebig BRD	Director/Board Member	73	01/17/01
Heinz Christoph Mäusli BRD	Director/Board Member	61	27/19/27
Frédéric Cren CEO	Chief Executive Officer	58	27/11/27
Pierre Broqua FOU	Founder	62	27/11/27
Martine Zimmermann BRD	Director/Board Member	55	16/21/16

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	52,115,807	41,644,337 ( 79.91 %)	0	79.91 %

Name	Equities	%	Valuation
BVF Partners LP 15.08 %	7,859,459	15.08 %	28 M €
Frédéric Cren 10.77 %	5,612,224	10.77 %	20 M €
Qatar Investment Authority (Investment Management) 9.896 %	5,157,233	9.896 %	18 M €
NEA Management Co. LLC 7.887 %	4,110,367	7.887 %	15 M €
Pierre Broqua 7.450 %	3,882,500	7.450 %	14 M €
Yiheng Capital Management LP 7.379 %	3,845,676	7.379 %	14 M €
DNCA Finance SA 0.4989 %	260,000	0.4989 %	932 256 €
Amundi Asset Management SA (Investment Management) 0.3580 %	186,579	0.3580 %	668 998 €
Jean Volatier 0.2874 %	149,800	0.2874 %	537 123 €
INVENTIVA 0.2168 %	113,003	0.2168 %	405 184 €

Name	Equities	%	Valuation
Yiheng Capital Management LP 5.075 %	2,644,926	5.075 %	10 M €
NEA Management Co. LLC 2.806 %	1,462,586	2.806 %	5 M €
BVF Partners LP 1.316 %	686,040	1.316 %	2 M €
BVF, Inc. 1.316 %	686,040	1.316 %	2 M €
Commonwealth Equity Services LLC 0.0696 %	36,265	0.0696 %	131 279 €
Two Sigma Securities LLC 0.0250 %	13,005	0.0250 %	47 078 €
EWA LLC 0.0228 %	11,898	0.0228 %	43 071 €
Morgan Stanley & Co. LLC 0.0113 %	5,900	0.0113 %	21 358 €
UBS Securities LLC 0.000487 %	254	0.000487 %	919 €

Name	Equities	%	Valuation
INVENTIVA 0.22%	113,003	0.22%	405,184 $

Inventiva SA

50, rue de Dijon

21121, Daix

+33 3 80 44 75 00

http://www.inventivapharma.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.97 EUR

Average target price

13.83 EUR

Spread / Average Target

+365.77%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
INVENTIVA	-27.47%	167M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs